Rapid Dose Therapeutics Corp. (RDTCF)
USD 0.18
(2150.0%)
USD 0.18
(2150.0%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 | 563.4 Thousand CAD | 51.29% |
| 2023 | 372.4 Thousand CAD | -72.31% |
| 2022 | 1.34 Million CAD | 548.24% |
| 2021 | 207.45 Thousand CAD | 455.63% |
| 2020 | 37.33 Thousand CAD | 123.89% |
| 2019 | -156.27 Thousand CAD | 0.0% |
| 2018 | - CAD | 0.0% |
| 2017 | - CAD | 0.0% |
| 2016 | - CAD | 0.0% |
| 2015 | - CAD | 0.0% |
| 2014 | - CAD | 0.0% |
| 2013 | - CAD | 0.0% |
| 2012 | - CAD | 0.0% |
| 2011 | - CAD | 0.0% |
| 2010 | - CAD | 0.0% |
| 2009 | - CAD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q3 | -450.14 Thousand CAD | -44.77% |
| 2024 FY | -1.41 Million CAD | -478.72% |
| 2024 Q4 | -262.67 Thousand CAD | 41.65% |
| 2024 Q2 | -310.93 Thousand CAD | -364.39% |
| 2024 Q1 | 117.6 Thousand CAD | 310.47% |
| 2023 Q4 | 28.65 Thousand CAD | -87.41% |
| 2023 Q2 | 84.87 Thousand CAD | 170.36% |
| 2023 Q3 | 227.48 Thousand CAD | 168.03% |
| 2023 Q1 | 31.39 Thousand CAD | -94.84% |
| 2023 FY | 372.4 Thousand CAD | -72.31% |
| 2022 Q3 | 359.17 Thousand CAD | 23.03% |
| 2022 FY | 1.34 Million CAD | 548.24% |
| 2022 Q4 | 608.81 Thousand CAD | 69.5% |
| 2022 Q1 | 84.87 Thousand CAD | 7.33% |
| 2022 Q2 | 291.94 Thousand CAD | 243.98% |
| 2021 Q3 | 124.98 Thousand CAD | 3861.55% |
| 2021 Q1 | -19.15 Thousand CAD | -357.84% |
| 2021 Q4 | 79.07 Thousand CAD | -36.73% |
| 2021 Q2 | 3155.00 CAD | 116.47% |
| 2021 FY | 207.45 Thousand CAD | 455.63% |
| 2020 Q3 | -891.58 Thousand CAD | -198.05% |
| 2020 FY | 37.33 Thousand CAD | 123.89% |
| 2020 Q1 | 12.13 Thousand CAD | 635.85% |
| 2020 Q2 | 909.36 Thousand CAD | 7392.47% |
| 2020 Q4 | 7428.00 CAD | 100.83% |
| 2019 Q4 | -2265.00 CAD | -205.5% |
| 2019 FY | -156.27 Thousand CAD | 0.0% |
| 2019 Q1 | - CAD | 0.0% |
| 2019 Q2 | - CAD | 0.0% |
| 2019 Q3 | 2147.00 CAD | 0.0% |
| 2018 Q3 | - CAD | 0.0% |
| 2018 Q1 | - CAD | 0.0% |
| 2018 Q2 | - CAD | 0.0% |
| 2018 FY | - CAD | 0.0% |
| 2018 Q4 | - CAD | 0.0% |
| 2017 Q4 | - CAD | 0.0% |
| 2017 Q3 | - CAD | 0.0% |
| 2017 Q2 | - CAD | 0.0% |
| 2017 FY | - CAD | 0.0% |
| 2017 Q1 | - CAD | 0.0% |
| 2016 Q4 | - CAD | 0.0% |
| 2016 FY | - CAD | 0.0% |
| 2016 Q3 | - CAD | 0.0% |
| 2016 Q2 | - CAD | 0.0% |
| 2016 Q1 | - CAD | 0.0% |
| 2015 FY | - CAD | 0.0% |
| 2015 Q3 | - CAD | 0.0% |
| 2015 Q2 | - CAD | 0.0% |
| 2015 Q1 | - CAD | 0.0% |
| 2015 Q4 | - CAD | 0.0% |
| 2014 Q2 | - CAD | 0.0% |
| 2014 Q3 | - CAD | 0.0% |
| 2014 Q4 | - CAD | 0.0% |
| 2014 Q1 | - CAD | 0.0% |
| 2014 FY | - CAD | 0.0% |
| 2013 Q4 | - CAD | 0.0% |
| 2013 FY | - CAD | 0.0% |
| 2013 Q1 | - CAD | 0.0% |
| 2013 Q2 | - CAD | 0.0% |
| 2013 Q3 | - CAD | 0.0% |
| 2012 Q1 | - CAD | 0.0% |
| 2012 Q2 | - CAD | 0.0% |
| 2012 Q3 | - CAD | 0.0% |
| 2012 Q4 | - CAD | 0.0% |
| 2012 FY | - CAD | 0.0% |
| 2011 Q3 | - CAD | 0.0% |
| 2011 Q4 | - CAD | 0.0% |
| 2011 FY | - CAD | 0.0% |
| 2011 Q1 | - CAD | 0.0% |
| 2011 Q2 | - CAD | 0.0% |
| 2010 Q3 | - CAD | 0.0% |
| 2010 Q1 | - CAD | 0.0% |
| 2010 FY | - CAD | 0.0% |
| 2010 Q4 | - CAD | 0.0% |
| 2010 Q2 | - CAD | 0.0% |
| 2009 Q4 | - CAD | 0.0% |
| 2009 Q3 | - CAD | 0.0% |
| 2009 FY | - CAD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Bioxytran, Inc. | -8285.00 USD | 6900.35% |
| Eiger BioPharmaceuticals, Inc. | 14.99 Million USD | 96.244% |
| Institute of Biomedical Research Corp. | - USD | -Infinity% |
| SQZ Biotechnologies Company | 9.79 Million USD | 94.247% |
| Intellipharmaceutics International Inc. | 65.72 Thousand USD | -757.183% |
| Evofem Biosciences, Inc. | 11.7 Million USD | 95.187% |
| Santhera Pharmaceuticals Holding AG | 119.1 Million USD | 99.527% |
| Propanc Biopharma, Inc. | -34.15 Thousand USD | 1749.807% |
| Marizyme, Inc. | 457.7 Thousand USD | -23.095% |
| Genus plc | 178.7 Million USD | 99.685% |
| Pharming Group N.V. | 220.1 Million USD | 99.744% |
| Therapeutic Solutions International, Inc. | 62.22 Thousand USD | -805.424% |
| CNBX Pharmaceuticals Inc. | 410.16 Thousand USD | -37.362% |
| Nymox Pharmaceutical Corporation | -11 Thousand USD | 5221.9% |
| ContraFect Corporation | -154 Thousand USD | 465.85% |
| RegeneRx Biopharmaceuticals, Inc. | 76.76 Thousand USD | -633.978% |
| IMV Inc. | -962.29 Thousand USD | 158.548% |
| AXIM Biotechnologies, Inc. | -387.5 Thousand USD | 245.395% |
| ONE Bio Corp. | 20.12 Million USD | 97.201% |
| RVL Pharmaceuticals plc | 40.26 Million USD | 98.601% |
| Mesoblast Limited | -35.16 Million USD | 101.602% |
| MultiCell Technologies, Inc. | 49.32 USD | -1142254.015% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 28.25 Million USD | 98.006% |
| Genscript Biotech Corporation | 409.55 Million USD | 99.862% |
| Neon Bloom, Inc. | - USD | -Infinity% |
| Mosaic ImmunoEngineering Inc. | - USD | -Infinity% |
| Nanobac Pharmaceuticals, Incorporated | 3102.00 USD | -18062.766% |
| Biomind Labs Inc. | -15.42 Thousand USD | 3752.807% |
| Provectus Biopharmaceuticals, Inc. | -1.14 Million USD | 149.354% |
| Oncotelic Therapeutics, Inc. | 70 Thousand USD | -704.87% |
| Skye Bioscience, Inc. | -124.25 Thousand USD | 553.444% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| VioQuest Pharmaceuticals, Inc. | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | -4952.00 USD | 11477.403% |
| PsyBio Therapeutics Corp. | -50 Thousand USD | 1226.818% |
| Arch Therapeutics, Inc. | -2439.00 USD | 23200.0% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Acro Biomedical Co., Ltd. | 140.5 Thousand USD | -301.003% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 48.9 Thousand USD | -1052.166% |
| Q BioMed Inc. | -8988.00 USD | 6368.458% |
| GB Sciences, Inc. | -624.00 USD | 90389.904% |
| Alpha Cognition Inc. | -86.02 Thousand USD | 754.914% |
| CSL Limited | 7.56 Billion USD | 99.993% |
| Agentix Corp. | - USD | -Infinity% |
| American Oriental Bioengineering, Inc. | 44.35 Million USD | 98.73% |
| Enzolytics Inc. | 30.7 Thousand USD | -1734.73% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Resverlogix Corp. | - USD | -Infinity% |
| Nuo Therapeutics, Inc. | 482.43 Thousand USD | -16.785% |
| MetaStat, Inc. | - USD | -Infinity% |
| Curative Biotechnology, Inc. | -97.51 Thousand USD | 677.766% |
| argenx SE | 1.1 Billion USD | 99.949% |
| Northwest Biotherapeutics, Inc. | -25.79 Million USD | 102.184% |
| HST Global, Inc. | - USD | -Infinity% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | - USD | -Infinity% |
| Halberd Corporation | -208.00 USD | 270969.712% |
| Endonovo Therapeutics, Inc. | -514.51 Thousand USD | 209.504% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| Zenith Capital Corp. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | - USD | -Infinity% |
| GeneThera, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | -8856.00 USD | 6461.89% |
| AVAX Technologies, Inc. | 617.38 Thousand USD | 8.743% |
| WPD Pharmaceuticals Inc. | - USD | -Infinity% |
| Cotinga Pharmaceuticals Inc. | -83.84 Thousand USD | 771.933% |
| Ember Therapeutics, Inc. | - USD | -Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Adynxx, Inc. | - USD | -Infinity% |
| NovAccess Global Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | 987.98 Thousand USD | 42.974% |
| Capstone Therapeutics Corp. | 9.61 Million USD | 94.138% |
| Kadimastem Ltd | -630.13 Thousand USD | 189.41% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| BioStem Technologies, Inc. | 15.42 Million USD | 96.347% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | - USD | -Infinity% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| LadRx Corporation | -11.83 Thousand USD | 4860.532% |
| Cell Source, Inc. | - USD | -Infinity% |
| ProtoKinetix, Incorporated | -48.25 Thousand USD | 1267.469% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | -219.103% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | -219.103% |
| Affymax, Inc. | 1.35 Million USD | 58.486% |
| Mobile Lads Corp. | - USD | -Infinity% |
| Itoco Inc. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | - USD | -Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | -Infinity% |
| International Stem Cell Corporation | 4.6 Million USD | 87.773% |
| CytoDyn Inc. | -29 Thousand USD | 2042.79% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Qrons Inc. | - USD | -Infinity% |
| Alseres Pharmaceuticals, Inc. | 450.04 Thousand USD | -25.19% |
| SYBLEU INC | 11.69 Thousand USD | -4717.108% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | -319.5 Thousand USD | 276.337% |
| Rebus Holdings, Inc. | - USD | -Infinity% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | - USD | -Infinity% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | - USD | -Infinity% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | - USD | -Infinity% |
| Innovation Pharmaceuticals Inc. | -373 Thousand USD | 251.048% |
| Neutra Corp. | 14.33 Thousand USD | -3830.303% |
| Windtree Therapeutics, Inc. | -82 Thousand USD | 787.084% |
| PureTech Health plc | -1.6 Million USD | 135.147% |
| Coeptis Therapeutics, Inc. | -1 Million USD | 156.271% |
| IXICO plc | 3.27 Million USD | 82.77% |
| IntelGenx Technologies Corp. | -694 Thousand USD | 181.183% |
| Gelesis Holdings, Inc. | -1.79 Million USD | 131.458% |
| CSL Limited | 7.7 Billion USD | 99.993% |
| Cellectis S.A. | 18 Thousand USD | -3030.05% |